fbpx

NBCA to Present at the 2022 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma

NBCA to Present at the 2022 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma

May 4, 2022

NBCA will be attending the 2022 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma. This conference will convene a multi-disciplinary group of stakeholders with wide ranging areas of expertise and focus in injury care and venous thromboembolism (VTE) in trauma. It will be a hybrid in-person/virtual event May 4-5, 2022, with the face-to-face portion held in Chicago, Illinois, at the American College of Surgeons.

Hear from NBCA Volunteer President and PE survivor, Leslie Lake,  as she provides the patient perspective, as reported by the patients themselves. Joining her will be Dr. Anna Newcomb, President of the American Trauma Society and Trauma Research Manager at Inova in Northern Virginia.

NBCA Board member and Vice Chair of Quality, Safety & Service and Associate Professor, Elliott R. Haut, MD, PhD, will present on several different topics including overcoming barriers to delivering VTE prophylaxis in inpatient settings and best practices for early VTE prevention.

Attendees will:

  1. Discuss guidelines for VTE prophylaxis in high-risk trauma patients that are accepted by trauma clinicians, surgical subspecialists, nurses, pharmacists, and patients that provide care to injured patients (and later help to disseminate these guidelines to respective specialty organizations)
  2. Address challenges to the dissemination and implementation of these guidelines across healthcare systems
  3. Define research priorities to measure short- and long-term outcomes for injured patients at risk for VTE, study the implementation of consensus guidelines, and investigate novel pharmacologic approaches to VTE prophylaxis
  4. Hear the voice of injured patients with VTE to promote patient-centered care research

Learn more, register, and see the agenda

Current News

The FUVID Study

June 29, 2022 The FUVID Study (Functional Characterization of Chronic Thromboembolic Venous Disease in Children) is currently open for enrollment…

CVS Caremark puts Eliquis® back on its formularies

In December of 2021, the National Blood Clot Alliance (NBCA) learned the largest pharmacy benefits manager (PBM) in the United…